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New Development of Vitamin K Research: Identification of
Human Menaquinone-4 Biosynthetic Enzyme
KIMIE NAKAGAWA
Department of Hygienic Sciences, Kobe Pharmaceutical University, Japan

ABSTRACT
Natural vitamin K is found in two forms: a plant form, phylloquinone (PK) and bacterial forms, menaquinones (MKs). In
many species, including humans, PK is a minor constituent of hepatic vitamin K content, with most hepatic vitamin K content
comprising long-chain MKs. Menaquinone-4 (MK-4) is ubiquitously present in extrahepatic tissues, with particularly high
concentrations in the brain, kidney and pancreas of humans and rats. It has consistently been shown that PK is endogenously
converted to MK-4. The molecular mechanisms for these conversion reactions have been unclear. To identify the MK-4
biosynthetic enzyme, we screened the human genome database for prenylation enzyme. We found UbiA prenyltransferase
domain containing 1 (UBIAD1), a human homologue of Escherichia coli prenyltransferase menA. The short interfering RNA
against the UBIAD1 gene inhibited the conversion of deuterium-labelled vitamin K derivatives into deuterium-labelled-MK-4
(MK-4-d7) in human cells. We confirmed that the UBIAD1 gene encodes an MK-4 biosynthetic enzyme through its expression
and conversion of deuterium-labelled vitamin K derivatives into MK-4-d7 in insect cells infected with UBIAD1 baculovirus.
UBIAD1 was localized in endoplasmic reticulum. Our results show that UBIAD1 is a human MK-4 biosynthetic enzyme; this
identification will permit more effective decisions to be made about vitamin K intake and bone health.
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INTRODUCTION
Vitamin K is a cofactor for γ-glutamyl carboxylase
(GGCX), an enzyme that converts specific glutamic acid
residues
in
several
substrate
proteins
to
γ-carboxyglutamic acid (Gla) residues(1-3). Gla residues
serve to form calcium-binding groups in proteins and are
essential for their biologic activity. Gla-containing
proteins are involved in blood coagulation(4), bone
metabolism(5), vascular repair(6), prevention of vascular
calcification(7), regulation of cell proliferation, and signal
transduction(8). Vitamin K undergoes a cyclic
interconversion, the vitamin K cycle, comprising
reduction of the vitamin K quinone form into the
hydroquinone, oxidation to 2,3-epoxide (vitamin K
epoxide), and reduction to the quinone. The formation of
Gla from glutamate is coupled with the conversion of the
hydroquinone to the vitamin K epoxide. Both of these
activities occur in GGCX. The warfarin-sensitive
microsomal enzyme, vitamin K epoxide reductase,
recycles the vitamin K epoxide back to the hydroquinone,
thus completing the vitamin K cycle(9-11). The metabolic
requirement for vitamin K is satisfied by dietary
phylloquinone (2-methyl-3-phytyl-1,4-naphthoquinone:
PK) present in plants and, to an undetermined extent, by a
bacterially produced series of 2-methyl-3-polyisoprenyl
homologues called menaquinones (MK-n) produced in


the lower bowel(12). Menadione (vitamin K3: K3),
commonly used in animal diets, is converted to
2-methyle-3-geranyl-geranyl-1,4-naphthoquinone (MK-4)
when administered to animals(13). A remarkable
observation in vitamin K disposition is the conversion of
PK into MK-4. Several reports showed that MK-4
accumulates in the tissues of rats following the
administration of PK(14). MK-4 was detected at low levels
in the plasma and liver, and at much higher levels in the
extrahepatic tissues such as the tissues in brain, pancreas,
thyroid gland, kidney and bone. It has been well known
since the 1960s that both K3 and PK are converted to
MK-4 in rats and chickens. Recent studies using
germ-free rats showed that the conversion of PK to MK-4
was independent of the gut flora(15,16). However, neither
the pathway nor the function of the conversion PK into
MK-4 is known. At the moment, two routes can be
supposed: first, desaturation of the phytyl side chain to
produce the geranylgeranyl group of MK-4; second,
removal of the phytyl side chain to release K3, which is
subsequently prenylated. Our recent report indicates that
cerebral MK-4 originates from not only systemic
conversion comprising the release of K3 from PK in the
intestine and the prenylation of K3 into MK-4 in the
cerebra but also the in-cell conversion of PK into MK-4
in cerebra(17). We used the stable isotope-labeled vitamin
K compounds. Stable isotope-labeled compounds are
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particularly useful for distinguishing the behavior of
exogenous compounds from that of the corresponding
endogenous compounds on the basis of structural
assignments by nuclear magnetic resonance (NMR)
spectrometry and liquid chromatography-tandem mass
spectrometry (LC-MS/MS). We synthesized deuterium
(D)- or heavy oxygen (18O)-labeled forms of PK and
MK-4 in our laboratory. Using these compounds, we
were able to obtain unequivocal evidence of the origin of
MK-4 in the cerebra of mice. Our findings suggest that
MK-4, a transcriptional regulator of steroid and
xenobiotic receptor (SXR)-mediated signaling(18) as well
as a cofactor for GGCX, is not simply a dietary nutrient,
but should be regarded as an active form of vitamin K
that may contribute to neural functions in mammals. In
our previous study, the PK-d7 to MK-4-d7 conversion
indeed occurred in the cerebral slice culture as well as
primary culture, however, neither neurons nor astrocyes
converted PK-d7 into MK-4-d7(17). The reason for these
conflicting results is as yet unclear.
Recently, we succeeded to identify a human MK-4
biosynthetic enzyme. We screened the human genome
database for prenylation enzymes and found UbiA
prenyltransferase containing 1 (UBIAD1), a human
homologue of Escherichia coli prenyltransferase menA.
We found that short interfering RNA against the UBIAD1
gene inhibited the conversion of deuterium-labelled
vitamin K derivatives into deuterium-labelled-MK-4
(MK-4-d7) in human cells. We confirmed that the
UBIAD1 gene encodes an MK-4 biosynthetic enzyme
through
its
expression
and
conversion
of
deuterium-labelled vitamin K derivatives into MK-4-d7 in
insect cells infected with UBIAD1 baculovirus(18).
UBIAD1 was localized in endoplasmic reticulum and
ubiquitously expressed in several tissues of mice. Our
results show that UBIAD1 is a human MK-4 biosynthetic
enzyme; this identification will permit more effective
decisions to be made about vitamin K intake and bone
health.

MK-4 BIOSYNTHESIS IN MOUSE
Stable isotope-labelled compounds are particularly
useful for distinguishing the behaviour of exogenous
compounds from that of the corresponding endogenous
compounds on the basis of structural assignments by
NMR spectrometry and LC-MS/MS. We synthesized Dor 18O-labelled forms of PK and MK-4 in our laboratory.
Using these compounds, we were able to obtain
unequivocal evidence regarding the origin of MK-4 in
cerebrum of mice. We examined whether orally
administered PK-d7 accumulates in cerebra as a converted
form of MK-4-d7. Two hundred female mice were orally
administered PK-d7 at a single dose of 10 mol/kg body
weight, and cerebra were collected at 24 h after
administration. After purification by HPLC, the MK-4
fraction was obtained; this contained MK-4 and MK-4-d7
in amounts of 3.8 and 2.0 mg, respectively. Because

ICoFF論文集.indd 372

tissue MK-4 has not yet been identified on the basis of
structural assignments in humans and animals, and it is
not known whether purified MK-4-d7 in the presence of
endogenous MK-4 can be identified by D NMR, we
analyzed the MK-4 fraction by 1H NMR spectroscopy.
Consequently, the values of resonance derived from the
2-methyl-1,4-naphthoquinone ring and the geranylgeranyl
side chain of the MK-4 fraction entirely coincided with
those of authentic MK-4. The values of resonance derived
from the D-labelled 2-methyl-1,4-naphthoquinone ring of
the MK-4 fraction exactly coincided with those of
authentic MK-4-d7. The LC-APCI-MS/MS MRM
chromatograms and MS spectra of the MK-4 fraction
were completely congruent with those of authentic MK-4
and MK-4-d7. Thus based on the results of the 1H NMR,
D NMR, and LC-APCI-MS/MS analyses it is evident that
MK-4 exists in cerebra of mice and originates from intake
of PK. To obtain insight into the metabolic sites where
PK is converted into MK-4, mice were orally, enterally,
or intravenously administered PK-d7 or K3-d8 as a single
dose of 10 mol/kg body weight, or were
intracerebroventricularly administered PK-d7 or K3-d8 at a
dose of 0.1 mol/kg body weight. After 24 h, the
concentrations of MK-4-d7 and its epoxide in cerebra
were measured by LC-APCI-MS/MS. With respect to the
oral route, both PK-d7 and K3-d8 induced accumulation of
MK-4-d7 or its epoxide, and conversion of PK-d7 to
MK-4-d7 was as efficient as that of K3-d8 to MK-4-d7.
With respect to the enteral route, both PK-d7 and K3-d8
induced accumulation of MK-4-d7 and its epoxide; as
expected, the efficiency with which PK-d7 was converted
to MK-4-d7 was similar to that observed by the oral route.
These results indicate that release of K3 from PK does not
necessarily require the aid of gastric juices. With respect
to the intravenous route, K3-d8 induced accumulation of
MK-4-d7 and its epoxide at low levels, but PK-d7 did not.
With respect to the intracerebroventricular route, K3-d8
induced accumulation of MK-4-d7 and its epoxide at low
levels, but PK-d7 did not. To examine whether the
conversion of PK-d7 or K3-d8 to MK-4-d7 occurs in a
physiological state, we carried out a dose-response study
by the oral route and confirmed that both PK-d7 and K3-d8
were linearly converted to MK-4-d7 and MK-4-d7
epoxide.

CONVERSION OF PK AND K3 TO MK-4 IN
HUMAN OSTEOBLAST-LIKE MG-63 CELLS
In mice, PK-d7 and D-labelled K3-d8 administration
led to high levels of tissue MK-4-d7, particularly in bone.
We examined conversion of PK-d7 and K3-d8 into
MK-4-d7 in human osteoblast-like MG-63 cells. In in
vitro assay, K3-d8 was converted into MK-4-d7 more
efficiently than PK-d7. It is postulated that conversion of
PK into MK-4 is a metabolic process involving enzymes
responsible for cleavage of the side chain of PK and
subsequent prenylation of K3. MK-4 plays a key role in
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bone homeostasis and is a clinically effective therapeutic
agent for osteoporosis. MK-4 is a transcriptional regulator
of bone marker genes in osteoblasts and potentiates bone
formation by activating the steroid and xenobiotic
receptor SXR(19). Our findings indicate that MK-4, a
transcriptional regulator of SXR-mediated signalling as
well as cofactor for GGCX, is not simply a dietary
nutrient but should also be regarded as an active form of
vitamin K that may contribute to bone formation in
mammals.

IDENTIFICATION OF MK-4 BIOSYNTHETIC
ENZYME
In E. coli, MKs are involved in several anaerobic
electron transport systems(20): it is the major transporter of
electrons under anaerobic growth conditions(21). Six genes
(menA, menB, menC, menD, menE and menF) are
involved in the biosynthetic pathway of MKs, and a key
reaction for menaquinone biosynthesis in E. coli is the
conversion of 1,4-dihydroxy-2-naphthoic acid (a bicyclic
naphthalenoid) to the membrane-bound demethylmenaquinone. The key enzyme catalysing this reaction is
encoded by menA(21). Several human homologues of the
E. coli menaquinone biosynthetic enzymes exist in the
human genome database. However, the biological
functions of these homologous genes remain unknown.
UBIAD1 was the first identified mammalian homologue
of E. coli menA. In E. coli, the menA gene encodes a
prenyltransferase that is involved in the vitamin K
biosynthetic pathway(21). However, the function of human
UBIAD1 has not been determined. Other prenylation
enzymes, UbiA in E. coli and COQ2 in the yeast
Saccharomyces cerevisiae, catalyse the prenylation of
p-hydroxybenzoate, a critical step in ubiquinone
biosynthesis.
In humans this step is catalysed by human COQ2, a
coenzyme Q2 homologue of prenyltransferase (in
yeast)(24). The low sequence homology between the
UBIAD1 and COQ2 genes imply a different role for
UBIAD1. We therefore predicted that either UBIAD1 or
COQ2 is a prenylation enzyme for MK-4 biosynthesis in
humans. To check this hypothesis, we used short
interfering RNA (siRNA) against UBIAD1 and COQ2
genes to test their abilities to inhibit the conversions of
K3-d8 and MK-4-d12 into MK-4-d7 in MG-63 cells. In
contrast with COQ2 siRNA, UBIAD1 siRNA strongly
decreased the conversions of K3-d8 and MK-4-d12 into
MK-4-d7. We also constructed a UBIAD1 expression
vector and analysed the K3-d8 into MK-4-d7 in UBIAD1
expression-vector-transfected MG-63 cells. MK-4-d7
levels were correlated with UBIAD1 messenger RNA
levels and UBIAD1 protein expression levels.
To confirm that we had identified the UBIAD1 gene
as relating to a biosynthetic enzyme for MK-4, we
expressed the most prevalent form of the enzyme in
Spodoptera frugiperda (Sf9) cells. UBIAD1 expression
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was detected in UBIAD1 baculovirus-infected and not in
control-infected Sf9 cells. Sf9 cells showed no
measurable conversion activity, but showed conversion
activity when infected with UBIAD1 baculovirus.

LOCALIZATION AND TISSUE EXPRESSION
OF UBIAD1
The UBIAD1 enzyme is speculated to be localized
in the endoplasmic reticulum (ER) on the basis of its
amino-acid structure. To study the subcellular localization
of UBIAD1, we generated constructs expressing green
fluorescent protein (GFP)-tagged UBIAD1 fusion
proteins (UBIAD1–GFP) for the stable transfection of
MG-63 cells. The green fluorescence of UBIAD1–GFP
decorated the mesh-like structure of the ER in the
cytoplasm and co-localized exactly with the red ER
marker label (ER-tracker Red) but did not co-localize
with the Golgi marker (4,4-difluoro-4-bora-3a,4a-diaza-sindacene (BODIPY)-TR ceramide). These results
strongly indicate that UBIAD1 is a biosynthetic enzyme
for MK-4 located in the ER.
We also examined the distributions of Ubiad1
mRNA in mouse tissues and found that mouse Ubiad1
mRNA was expressed ubiquitously in all tissues tested.
We measured the concentrations of MK-4, MK-4-d7 and
their epoxides in several tissues, including the cerebrum,
liver and pancreas of mice orally administered with
PK-d7. MK-4-d7 biosynthetic activity was correlated with
mouse Ubiad1 mRNA expression in tissues, except for
the heart. Further, the tissue accumulation patterns of
MK-4-d7 and its epoxide coincided with those of
endogenous MK-4 and its epoxide. The expression of
Ubiad1 mRNA in heart was highest in the tissues tested,
whereas the concentrations of MK-4, MK-4-d7 and their
epoxides were relatively low. This may suggest an
unknown function of UBIAD1 in addition to MK-4
biosynthesis. Taken together, our results strongly suggest
that PK is converted to MK-4 by UBIAD1 and
accumulates as MK-4 in tissues.

UBIAD1 HAS THE SIDE-CHAIN CLEAVAGE
ACTIVITY AND PRENYLATION ACTIVITY
To ascertain the mechanism for the side-chain
cleavage and prenylation activities of UBIAD1, we
measured UBIAD1 activity by using the microsomal
fraction of UBIAD1 baculovirus-infected Sf9 cells. As
the results, we detected the activity of UBIAD1 in
converting MK-4-d7 from PK-d7 and K3-d8 in the
microsomes. Moreover, the prenylation activity of
UBIAD1 was the side-chain substrate (geranylgeranyl
pyrophosphate, GGPP) dose-dependent manner. These
results suggest that UBIAD1 is a novel biosynthetic
enzyme for MK-4 that may have both side-chain cleavage
and prenylation activities.
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CONCLUSIONS
Vitamin K is an important factor in proper blood
clotting and bone metabolism. MK-4 is not a main
bacterial product. MK-4 has a highly specific tissue
distribution suggestive of local synthesis from PK, the
primary dietary form of vitamin K. However, human
MK-4 biosynthesis enzyme has never studied so far. We
identified UBIAD1 as a key enzyme for human MK-4
biosynthesis. The function of UBIAD1 is unknown
though it has been reported as the candidate gene of
Schnyder crystalline corneal dystrophy (SCD), an
autosomal dominant disorder involving deposition of
cholesterol in the corneal stroma(22). Our finding offer
conclusive proof that the biosynthesized MK-4 by
UBIAD1 is an important factor with the function as the
hormone for anticoagulant therapy, bone health and SCD
therapy.
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